SynthesisCurrent pharmaceutical design2026
Therapeutic Potential of Stem Cells in the Treatment and Management of Immunomodulatory Disorders.
Synthesis in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmunomodulatory disorders, such as autoimmune diseases, inflammatory conditions, and viral infections, stem from immune system dysregulation and often resist conventional therapies. Stem cells, particularly mesenchymal (MSCs) and hematopoietic stem cells (HSCs), possess immunomodulatory and regenerative properties, offering a promising therapeutic alternative. METHODOLOGY: A systematic literature review was conducted using databases, including PubMed, Scopus, Web of Science, and Google Scholar, for studies published between 1996 and 2025. A total of 287 articles were screened, and 132 were selected based on relevance, quality, and focus on stem cell biology, immunoregulatory mechanisms, and therapeutic applications.
resultsStem cells demonstrated significant capacity to regulate immune responses, suppress the production of inflammatory cytokines, enhance regulatory T-cell populations, and promote tissue regeneration. HSCs are effectively used in hematologic malignancies and immune reconstitution, while MSCs show promise in treating conditions, such as rheumatoid arthritis, diabetes mellitus, and influenza-induced lung injury. Emerging evidence also supports the role of cancer stem cells (CSCs) in targeted cancer therapies. DISCUSSION: Stem cells offer a mechanism-driven approach to restoring immune balance and repairing tissue damage. However, variability in clinical outcomes, ethical concerns, and safety risks, such as tumorigenesis, limit their translation into clinical practice. Advances in cell derivation, immunomodulatory profiling, and delivery systems are critical to optimizing outcomes.
conclusionStem cell-based therapies represent a paradigm shift in the treatment of immunomodulatory disorders by addressing the root cause of immune dysfunction. Continued research, ethical oversight, and clinical validation are crucial for transitioning stem cell therapy into routine medical practice.
Indexed as
Identifiers
41691693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.